Stifel Nicolaus upgraded shares of Knight Therapeutics (TSE:GUD) to a buy rating in a research note issued to investors on Wednesday morning, TipRanks reports. Stifel Nicolaus currently has C$6.50 price target on the stock.
GUD has been the subject of several other research reports. Royal Bank of Canada restated an outperform rating and issued a C$7.50 target price on shares of Knight Therapeutics in a research note on Tuesday, July 13th. Raymond James reiterated an outperform rating and issued a C$8.50 price objective on shares of Knight Therapeutics in a research note on Tuesday, August 17th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of C$7.60.
GUD stock opened at C$5.43 on Wednesday. Knight Therapeutics has a one year low of C$4.88 and a one year high of C$5.97. The stock has a market capitalization of C$668.44 million and a PE ratio of 11.88. The company has a debt-to-equity ratio of 4.48, a quick ratio of 2.24 and a current ratio of 2.80. The company has a fifty day moving average of C$5.29 and a 200-day moving average of C$5.30.
Knight Therapeutics Company Profile
Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer.
Recommended Story: How to start trading in the forex market?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.